Chronic kidney disease

Chinook Therapeutics Announces Pricing of an Upsized $160 Million Public Offering

Retrieved on: 
Wednesday, November 10, 2021
808, Form, Private Securities Litigation Reform Act, Therapy, S-3, Prospectus, Security (finance), SEC filing, Chronic kidney disease, RNA, IgA nephropathy, Oppenheimer Holdings, Primary hyperoxaluria, Telephone, Research, Attention, Immunoglobulin A, Sale, LDHA, U.S. Securities and Exchange Commission, GLOBE, Kidney, State Street, Atrasentan, SEC, Nasdaq, Equity capital markets, SVB Leerink, Patient, Pharmaceutical industry

SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its upsized underwritten public offering of 7,828,572 shares of its common stock at a price to the public of $14.00 per share.

Key Points: 
  • SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its upsized underwritten public offering of 7,828,572 shares of its common stock at a price to the public of $14.00 per share.
  • The gross proceeds to Chinook from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chinook, are expected to be $159.6 million.
  • In addition, Chinook has granted the underwriters a 30-day option to purchase up to an additional 1,710,000 shares of common stock in connection with the public offering.
  • The offering is expected to close on or about November 15, 2021, subject to the satisfaction of customary closing conditions.

DiaMedica Therapeutics to Attend the 12th Annual Craig-Hallum Alpha Select Conference November 16, 2021

Retrieved on: 
Tuesday, November 9, 2021
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, AIS, KLK1, CKD, Therapy, Nasdaq, Conference, Lists of diseases, Kidney, DMAC, Chronic kidney disease, Remedy, Pharmaceutical industry

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that it will be participating in the 12th Annual Craig-Hallum Alpha Select Conference being held virtually on Tuesday, November 16, 2021.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that it will be participating in the 12th Annual Craig-Hallum Alpha Select Conference being held virtually on Tuesday, November 16, 2021.
  • Management will be available to participate in one-on-one meetings.
  • Investors and attendees that would like to schedule a meeting with DiaMedicas management can contact their Craig-Hallum representative to arrange a meeting.
  • DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering serious diseases.

Kezar Reports Third Quarter Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 9, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Mortality, Safety, Associate, Private Securities Litigation Reform Act, SLE, Chronic kidney disease, MD, Ohio State University, Cytokine, Investor relations, U.S. Securities and Exchange Commission, Endoplasmic reticulum, Disease, PM, Lupus nephritis, Inflammation, Muscle, COVID-19, Dermatomyositis, Research, Ohio, Forward-looking statement, Total, Dialysis, List of life sciences, Association, Foreign policy, Protein, Myopathy, TIS, Disclosure, Therapy, Degenerative disease, Pharmacokinetics, Diagnosis, Death, Ohio State University Wexner Medical Center, Public relations, ATM, Skin, Cell, UPCR, Patient, Immunosuppression, Risk, Respiration, IND, Pharmaceutical industry, Construction, Vaccine, KZR-616, KZR-261, Lupus Nephritis, Dermatomyositis and Polymyositis, Inhibition of Protein Secretion, Kezar Life Sciences, KZR-616, KZR-261, LUPUS NEPHRITIS, DERMATOMYOSITIS AND POLYMYOSITIS, INHIBITION OF PROTEIN SECRETION, KEZAR LIFE SCIENCES

Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2021 and provided a business update.

Key Points: 
  • Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2021 and provided a business update.
  • Kezar expects to report topline data in the second quarter of 2022.
  • Kezar expects to report topline data in the second quarter of 2022.
  • Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Global Biosimilars Market (2021 to 2026) - Patent Expiry of Blockbuster Biologics and Research on New Indications Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 9, 2021
General Health, Health, Science, Pharmaceutical, Research, Adoption, Cancer, Chronic condition, Myocardial infarction, IgG4-related ophthalmic disease, Degenerative disease, USD, Infection, CAGR, Multiple sclerosis, Hypoglycemia, Growth, Rheumatoid arthritis, Investment, Infertility, Chronic kidney disease, Trastuzumab, Rituximab, Macular degeneration, Incidence, Etanercept, Insulin, Asia, Monoclonality, Interferon, Oncology, Infliximab, Autoimmune disease, Conditional sentence, Osteoporosis, Prevalence, Patient, Vaccine, Generic drug

The global biosimilars market is projected to reach USD 44.7 billion by 2026 from USD 15.6 billion in 2021, at a CAGR of 23.5% during the forecast period of 2021 to 2026.

Key Points: 
  • The global biosimilars market is projected to reach USD 44.7 billion by 2026 from USD 15.6 billion in 2021, at a CAGR of 23.5% during the forecast period of 2021 to 2026.
  • Market growth is largely driven by the rising incidence of chronic diseases and increasing demand of biosimilars for their cost-effectiveness.
  • Regulatory approvals and other regulations favouring biosimilars adoption in different countries is also a major driving factor in the biosimilars market.
  • The biosimilars market is segmented into Europe, Asia Pacific, North America, Latin America and Middle East and Africa.

Gilead to Present Data From Liver Disease Development Programs at The Liver Meeting®

Retrieved on: 
Tuesday, November 9, 2021
Biotechnology, Hospitals, Health, Pharmaceutical, Clinical Trials, HDV, Nasdaq, Safety, Fatty liver disease, American Association, American Association for the Study of Liver Diseases, TDF, MD, Cirrhosis, Fasting, HBV, Sofosbuvir/velpatasvir, Breakthrough therapy, Doctor of Philosophy, World, Liver disease, EMA, Food, Liver cancer, AASLD, European Medicines Agency, Institute of Liver and Biliary Sciences, Moyamoya disease, Chronic kidney disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HIV disease progression rates, Priority, TAF, Association, Woman, Liver, NASH, Hepatitis C, Bulevirtide, Death, HCV, Weight loss, Science, Patient, Risk, FDA, Gilead Sciences, Pharmaceutical industry

Were excited to share data from our robust clinical development programs at AASLDs The Liver Meeting,including the latest data demonstrating the positive impacts of bulevirtide for people living with HDV.

Key Points: 
  • Were excited to share data from our robust clinical development programs at AASLDs The Liver Meeting,including the latest data demonstrating the positive impacts of bulevirtide for people living with HDV.
  • Vemlidy is indicated for the treatment of chronic HBV in adults with compensated liver disease.
  • Epclusa, Hepcludex, Vemlidy, Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
  • For more information about Gilead, please visit the companys website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

New Analysis to be Presented at the American Heart Association Scientific Sessions 2021 Evaluating Cardiovascular Benefits Across Baseline Kidney Function

Retrieved on: 
Tuesday, November 9, 2021
Science, AHA, The New England Journal of Medicine, Form 10-K, Type 2 diabetes, Medicine, Security (finance), Brigham and Women's Hospital, Hospital, Disease, Gene, American Heart Association, Harvard Medical School, Neuropathic pain, Diabetes, Chronic kidney disease, Cardiovascular disease, Annual report, Protein, U.S. Securities and Exchange Commission, GLOBE, Holocene, Heart failure, Metabolism, Treating, NEJM, Nasdaq, EGFR, Death, Intellectual property, Pharmaceutical industry

THE WOODLANDS, Texas, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that a new analysis of sotagliflozin results from the SOLOIST and SCORED Phase 3 outcomes studies will be presented at the virtual American Heart Association Scientific Sessions 2021.

Key Points: 
  • THE WOODLANDS, Texas, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that a new analysis of sotagliflozin results from the SOLOIST and SCORED Phase 3 outcomes studies will be presented at the virtual American Heart Association Scientific Sessions 2021.
  • The presentation is entitled, Cardiovascular Benefits of Sodium Glucose Cotransporter-1/2 Inhibition with Sotagliflozin Across Baseline Kidney Function.
  • The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo.
  • Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Introducing the Truveta Platform: Unprecedented De-Identified Health Data Refreshed Daily with New COVID-19 Insights

Retrieved on: 
Tuesday, November 9, 2021
People, Health, Learning, Safety, Providence Portland Medical Center, Public health, Cancer, Â, FHIR, Ochsner Health System, Estes, Genomics, Infection, SNOMED CT, Sex, CEO, Comorbidity, LOINC, Doctor of Philosophy, HIV, Failure, Pfizer, Death, SNOMED, Machine learning, Degenerative disease, Project Jupyter, COVID-19, Geography, Research, Chronic kidney disease, API, AI, Kidney disease, HIPAA, Twitter, Hospital, GLOBE, LinkedIn, UnityPoint Health, RxNorm, Johnson & Johnson, Solution, Trustee, Therapy, Physician, Diabetes, Asthma, Patient, EHR, Clinical research, Medical device, Pharmaceutical industry, Medical imaging, Medicine

With the moral imperative to address this significant gap, Truveta was born from innovative health systems who came together to deliver an unprecedented national dataset for US health.

Key Points: 
  • With the moral imperative to address this significant gap, Truveta was born from innovative health systems who came together to deliver an unprecedented national dataset for US health.
  • Now, Truveta is sharing the first COVID-19 insights in the US using real-time data, representing a major step forward in realizing our vision of saving lives with data.
  • Data is refreshed daily and continuously flowing, providing researchers with an unprecedented opportunity to learn about our nations health every day.
  • Insights generated from the Truveta Platform are real-time and updated daily as data from more health systems is de-identified and integrated into the Truveta Platform, revealing up-to-date insights as the nations health evolves.

Tricida Announces Third Quarter 2021 Financial Results

Retrieved on: 
Monday, November 8, 2021
CKD, Chronic kidney disease, Type, SAN, Glomerular filtration rate, EGFR, Food, Investment, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ESRD, Conference, GLOBE, Webcast, Patient, Risk, FDA, Metabolic acidosis, Pharmaceutical industry, Dietary supplement, Cryptocurrency

As of November 5, 2021, the trial has randomized over 1,470 of its planned 1,600 subjects with an average treatment duration of approximately 19 months.

Key Points: 
  • As of November 5, 2021, the trial has randomized over 1,470 of its planned 1,600 subjects with an average treatment duration of approximately 19 months.
  • Financial Results for the Three and Nine Months Ended September 30, 2021
    Research and development expense was $26.6 million and $43.0 million for the three months ended September 30, 2021 and 2020, respectively.
  • General and administrative expense was $9.1 million and $29.3 million for the three months ended September 30, 2021 and 2020, respectively.
  • Tricida will host its Third Quarter Financial Results and Business Update Conference Call and webcast today at 4:30 pm Eastern Time.

Sustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021

Retrieved on: 
Monday, November 8, 2021
Securities Exchange Act of 1934, University, Plasma, SAN, Kidney, NASDAQ, Department, Liver, Titan Pharmaceuticals, Society, CA, University of Washington station, Securities Act of 1933, Chronic kidney disease, Proneura prolongata, Department of Pharmacology, University College London, Drug Quality and Security Act, Mouse, Marketing, Patent, Patient, Atopic dermatitis, Executive, Pharmaceutical industry, Medical device

As previously reported , low dose TP-2021 implants had demonstrated anti-pruritic effects for up to 2 weeks in this model.

Key Points: 
  • As previously reported , low dose TP-2021 implants had demonstrated anti-pruritic effects for up to 2 weeks in this model.
  • A significant reduction in scratching behavior was maintained in mice who received the high-dose TP-2021 implant at both Day 28 and Day 56 post-implantation, compared with those that received the placebo implant, with no safety issues observed.
  • In addition, the high-dose TP-2021 implant provided sustained supra-therapeutic plasma levels of TP-2021 through Day 84.
  • "Difelikefalin (Korsuva)) intravenous injection set the guidepost for the treatment of chronic kidney disease patients undergoing hemodialysis.

Cara Therapeutics Reports Third Quarter 2021 Financial Results

Retrieved on: 
Monday, November 8, 2021
Safety, Achievement, Priority review, Oral, Therapy, CMS, Medicare, KARE, Non, MAA, Food and Drug Administration, European Union, CEO, Leo Pharma, EMA, Food, European Medicines Agency, Union, Centers for Medicare & Medicaid Services, Chronic kidney disease, Dialysis, Conference call, Â, Doctor of Philosophy, Patient, Conference, Company, Marketing, GLOBE, Itch, New Drug Application, Diagnosis, BSA, KORS, Nasdaq, Atopic dermatitis, FDA, Health care, Documentation, Pharmaceutical industry, Management

STAMFORD, Conn., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced financial results and operational highlights for the third quarter ended September 30, 2021.

Key Points: 
  • ET
    STAMFORD, Conn., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced financial results and operational highlights for the third quarter ended September 30, 2021.
  • In the third quarter of 2021, Cara made significant progress across our development programs, culminating with the FDA approval of KORSUVA injection for moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients, said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics.
  • Third Quarter and Recent Developments:
    In November 2021, the Company announced the appointment of Christopher Posner as President and Chief Executive Officer of Cara Therapeutics, effective November 9, 2021.
  • ET to discuss third quarter 2021 financial results and provide a business update.